Reducing the Cost of the Cure in Childhood Leukemia

Publisher Website
Google Scholar
Abstract
Current therapy cures most children with acute lymphoblastic leukemia (ALL). Two thirds of the patients have favorable prognostic features at the time their ALL is diagnosed, and the results of the latest clinical trials strongly suggest that almost 90 percent of them will be cured. The favorable prognostic features include an age between 2 and 10 years, a low white-cell count, the absence of massive hepatosplenomegaly and central nervous system involvement, and the absence of cell-membrane-immunoglobulin and T-lymphoid markers. ALL has become an emotionally rewarding disease to treat; the clinical discoveries that led to this gratifying state of the art . . .